Lantheus Holdings, Inc. splits its revenue into 9 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was PYLARIFY at $989.1 million, 64% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1,556
|
1,542
|
1,534
|
1,296
|
935
|
425
|
339
|
347
|
343
|
331
|
302
|
| Product |
—
|
—
|
1,525
+20.7%
share 99.4%
|
1,263
+42.4%
share 97.4%
|
887
share 94.9%
|
—
|
—
|
—
|
—
|
—
|
—
|
| PYLARIFY |
—
|
989
-6.5%
share 64.2%
|
1,058
+24.3%
share 69.0%
|
851
+61.4%
share 65.7%
|
527
+1114.8%
share 56.4%
|
43
share 10.2%
|
—
|
—
|
—
|
—
|
—
|
| Definity |
—
|
330
+3.9%
share 21.4%
|
318
+13.6%
share 20.7%
|
280
+14.2%
share 21.6%
|
245
+5.3%
share 26.2%
|
233
+18.8%
share 54.7%
|
196
-3.2%
share 57.7%
|
202
share 58.3%
|
—
|
—
|
—
|
| Techne Lite |
—
|
87
-9.1%
share 5.6%
|
95
share 6.2%
|
—
|
89
-2.7%
share 9.5%
|
91
+7.5%
share 21.5%
|
85
-0.6%
share 25.0%
|
85
share 24.6%
|
—
|
—
|
—
|
| Neuraceq |
—
|
51
share 3.3%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Strategic Partnerships And Other |
—
|
—
|
38
-26.4%
share 2.5%
|
52
+10.7%
share 4.0%
|
47
+85.3%
share 5.0%
|
25
+115.2%
share 5.9%
|
12
+645.8%
share 3.5%
|
2
share 0.5%
|
—
|
—
|
—
|
| Licenseand Royalty Revenues |
—
|
34
+272.9%
share 2.2%
|
9
-72.6%
share 0.6%
|
33
-30.5%
share 2.6%
|
48
+93.2%
share 5.1%
|
25
+112.1%
share 5.8%
|
12
+468.4%
share 3.5%
|
2
share 0.6%
|
—
|
—
|
—
|
| Other Precision Diagnostics |
—
|
25
+1.6%
share 1.6%
|
24
+5.4%
share 1.6%
|
23
+0.7%
share 1.8%
|
23
-15.4%
share 2.4%
|
27
-26.8%
share 6.3%
|
37
-25.2%
share 10.8%
|
49
share 14.2%
|
—
|
—
|
—
|
| Other Radiopharmaceutical Oncology |
—
|
—
|
0
-87.7%
share 0.0%
|
3
-23.7%
share 0.2%
|
4
-25.1%
share 0.4%
|
5
-45.4%
share 1.3%
|
10
+15.8%
share 3.0%
|
9
share 2.5%
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- LNTH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bedford, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1521036
- Former names
- Lantheus MI Holdings, Inc. (until May 23, 2014)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.